Please login to the form below

Not currently logged in
Email:
Password:

AZ in global AI licence agreement

AstraZeneca has completed a global licensing agreement for Meditrina Pharmaceuticals to use its intellectual property in developing, manufacturing and commercialising combinations of aromatase inhibitors with oestrogen and progestin to treat endometriosis. The terms of the agreement were not disclosed.

AstraZeneca has completed a global licensing agreement for Meditrina Pharmaceuticals to use its intellectual property in developing, manufacturing and commercialising combinations of aromatase inhibitors with oestrogen and progestin to treat endometriosis. The terms of the agreement were not disclosed.

Prior to the deal completing, Meditrina, a drugs company specialising in therapies for disorders of the female reproductive system, was already working on Femathina, an AI compound which the firm is repurposing. It recently completed a phase II trial and is being tested for "several serious women's health conditions", including endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding.

Meditrina anticipates developing and marketing "a product" in female healthcare in the US, though the firm said it would consider partnering in order to reach other markets worldwide. 

The AZ deal aims to find new treatments specifically for endometriosis, a condition occurring when endometrial stroma and glands are found outside of their normal location in the uterine cavity. According to estimates, up to 10 per cent of all women can be affected by endometriosis, including up to 87 per cent of women with chronic pelvic pain and up to 40 per cent of those suffering with infertility.

"Meditrina will be pursuing this indication, leveraging the work done to date by AstraZeneca," said executive director of R&D at AZ, John Patterson.

6th February 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is the UK arm of Zeno Group, a global integrated communications consultancy. Everything we do is rooted...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics